

# CONTENTS

Vol.42 No.3 May 2011

Japanese Journal of Clinical Pharmacology  
and Therapeutics

## **Original**

- Comparison of the Characteristics of Rheumatoid Arthritis Patients in  
Clinical Trials and Clinical Practice Waki MORITA, et al. 111

## **Forum**

- Contribution of Visiting CRC to Clinical Trials in Ehime University Hospital  
Clinical Research Trial Network Chieko YAMASAKI, et al. 117
- Development of Training Materials for Clinical Research Education Utilizing  
Simulated Registration to UMIN-CTR Operated by the University hospital  
Medical Information Network (UMIN) Naoki MATSUMOTO, et al. 121

## **Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics**

- Contents 129
- Symposium 3 "Cell Therapy" 133
- Symposium 9 "Clinical Pharmacology of Drug Transporters" 143
- Symposium 14 "Strategies for the Promotion of Clinical Trials in Japan" 155
- Symposium 15 "Molecular-Targetted Drugs and Biomarkers" 165
- Symposium 18 "The Contribution of Clinical Pharmacology Departments  
to Study the Pathological Pharmacokinetics" 171
- Symposium 19 "Chronic Kidney Disease (CKD) and New Therapeutic Approach" 183
- Symposium 23 "Perspective of Order-Made Pharmacotherapy in Psychiatry" 195

**Drug Information** 91E

**Information for Authors** 95E

**Announcements** 97E

**Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology  
and Therapeutics**

December 1–3, 2010 (Kyoto)

President: Ken-ichi INUI (Emeritus Professor, Kyoto University/President, Kyoto Pharmaceutical University)

**Symposium 3 “Cell Therapy”**

Summary	Takafumi KIMURA, et al.	133
S3-1 A New Era of Adoptive T Cell Therapy for Cancer	Hiroaki IKEDA	135
S3-2 Clinical Trial for Osteonecrosis Using Autologous Mesenchymal Stem Cells	Tomoki AOYAMA, et al.	137
S3-3 Treatment of Retinal Diseases Using iPS Cells	Masayo TAKAHASHI	139
S3-4 The Trend of iPS Cell Research	Takashi AOI	141

**Symposium 9 “Clinical Pharmacology of Drug Transporters”**

S9-1 Clinical Significance of Renal Drug Transporters in Human	Hideyuki MOTOHASHI	143
S9-2 <i>SLCO2B1</i> Gene Polymorphisms in Humans	Yukie ANDO, et al.	145
S9-3 Renal Tubular Excretion of Uremic Toxins : A Novel Therapeutic Modality for Chronic Kidney Disease by Enhancement of Uremic Toxin Transporter	Takehiro SUZUKI, et al.	147
S9-4 Drug Transport Mediated by a Novel Human Voltage-Driven Organic Anion Transporter NPT4 ( <i>SLC17A3</i> )	Naohiko ANZAI	149
S9-5 Different Influences of CYP2C19 Gene Polymorphisms on the Antiplatelet Effect of Clopidogrel and Ticlopidine	Akimitsu MAEDA, et al.	151
S9-6 Toward PGx-Guided “Personalized Medicine” : Multicenter Randomized Pharmacogenomic Trial for Tuberculosis Therapy	Masako OHNO, et al.	153

**Symposium 14 “Strategies for the Promotion of Clinical Trials in Japan”**

Summary	Hideo KUSUOKA, et al.	155
S14-1 The Present Situation and Prospect of Clinical Trials in the National Hospital Organization	Suminobu ITO	157
S14-2 About the Enforcement Support of Investigator-Initiated Clinical Trials	Manabu YAMAMOTO	159
S14-3 New Challenge of Proceeding Clinical Study in Chiba University Hospital	Hideki HANAOKA, et al.	161
S14-4 Japan’s Policies for Clinical Studies	Takeyuki SATO	163

**Symposium 15 “Molecular-Targetted Drugs and Biomarkers”**

S15-1 Genome Biomarker of Molecular Targetting Therapy for Gastrointestinal Disorders	Takahisa FURUTA, et al.	165
S15-2 Biomarker Hunting for Pharmacogenomics	Gozoh TSUJIMOTO	167
S15-3 Omics Drug Discovery and Target Validation	Toshio TANAKA, et al.	169

**Symposium 18 “The Contribution of Clinical Pharmacology Departments  
to Study the Pathological Pharmacokinetics”**

Summary	Masahiro NOMOTO, et al.	171
S18-1 Clinical Pharmacokinetic Studies with Patients on New Drug Applications : Regulator Views in Japan	Reiko SATO	173
S18-2 Opportunities and Challenges of a University-Based Phase I Research Unit —Experience at the University of Miami—	Richard A. Preston	175
S18-3 Pharmacokinetic Studies in Patients and Applications to the Treatment	Masahiro NOMOTO	179
S18-4 The Remark from the Planners of Pharmacokinetic Study for Special Population	Koji IWASAKI	181

## Symposium 19 “Chronic Kidney Disease (CKD) and New Therapeutic Approach”

Summary		<b>Toshio DOI, et al.</b>	183
S19-1	The Basic Concept and Therapeutic Strategy for Chronic Kidney Disease (CKD)	<b>Naoki KASHIHARA</b>	185
S19-2	Role of Endothelial Dysfunction in Cardiorenal Syndrome	<b>Seiji UEDA, et al.</b>	187
S19-3	Strategies for Therapeutic Targeting of the BMP4-Smad1 Signaling Pathway in Diabetic Nephropathy	<b>Hideharu ABE</b>	189
S19-4	Chronic Kidney Disease and Mineralocorticoids	<b>Miki NAGASE</b>	191
S19-5	New Strategy for Overcoming CKD with the RAS Inhibitors	<b>Akira NISHIYAMA</b>	193

## Symposium 23 “Perspective of Order-Made Pharmacotherapy in Psychiatry”

Summary		<b>Kazutaka SHIMODA, et al.</b>	195
S23-1	Predictors of Side Effects Induced by Atypical Antipsychotics	<b>Yutaro SUZUKI, et al.</b>	197
S23-2	Possibility of Pharmacogenetic Approach for Prediction and Personalized Medication in Major Depressive Disorder Treatment	<b>Masaki KATO</b>	199
S23-3	Clinical Pharmacogenetics in the Treatment of Schizophrenia	<b>Norio YASUI-FURUKORI</b>	201
S23-4	Perspective of Order-Made Pharmacotherapy in Anxiety Disorder	<b>Takashi WATANABE, et al.</b>	203